Drug Profile
Azelastine/fluticasone propionate - Cipla/Meda
Alternative Names: Azelastine hydrochloride/fluticasone propionate; Duonase; Dymista; Dymista D; Dymistalan; Dymistin; Dymolin; Fluticasone propionate/azelastine hydrochloride; Flutista; MP 29-01; MP 29-02; MP-AzeFluLatest Information Update: 20 Dec 2021
Price :
$50
*
At a glance
- Originator Meda
- Developer Cipla; Meda; Mylan
- Class Antiallergics; Glucocorticoids; Phthalazines; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic rhinitis; Perennial allergic rhinitis; Seasonal allergic rhinitis
Most Recent Events
- 27 Oct 2021 Launched for Allergic rhinitis in Taiwan, Thailand (Intranasal) (NCT05158972)
- 01 Oct 2021 Registered for Allergic rhinitis in Taiwan, Thailand (Intranasal) (NCT05158972)
- 01 Aug 2019 No development reported - Preregistration for Allergic rhinitis in China, South Africa, Middle East (Intranasal)